Butterfly Network (BFLY) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Achieved record Q2 2024 revenue of $21.5 million, up 16% year-over-year, driven by iQ3 launch, strong international growth, and new product introductions.
Net loss narrowed to $15.7 million from $28.7 million in Q2 2023, reflecting significant cost reductions and improved gross profit.
Achieved $10 million in annualized cost savings through workforce optimization and a global technology partnership, extending cash runway into 2027.
Expanded market reach with iQ3 launches in Canada, Southeast Asia, and a new Campus Essentials program for medical schools.
WHO recognized iQ+ in its 2024 Compendium for low-resource settings.
Financial highlights
Q2 2024 revenue: $21.5 million (16% YoY growth), highest in company history.
Product revenue: $14.6 million (+19% YoY); software/services: $6.8–$6.9 million (+10% YoY), representing 31.8–32% of total revenue.
Gross profit: $12.6 million; gross margin: 58.6% (down 0.5pp YoY).
Operating expenses: $29.8 million (down 29% YoY); adjusted EBITDA loss: $8.1 million (improved from $17.0 million YoY).
Cash, cash equivalents, and restricted cash: $106.1 million as of June 30, 2024; net cash used in operating activities for H1 2024 was $30.7 million.
Outlook and guidance
Affirmed FY 2024 revenue guidance of $75–$80 million (15–20% growth YoY).
Improved full-year adjusted EBITDA loss guidance to $45–$50 million.
Q3 2024 revenue expected at ~$19 million (20–25% growth); adjusted EBITDA loss of $9–$10 million.
Cash runway extends into 2027, with plans to seek additional capital before then to reach profitability.
Annual cost savings of $10 million anticipated from a new global technology partnership.
Latest events from Butterfly Network
- AI-powered handheld ultrasound and new partnerships set stage for strong growth through 2026.BFLY
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - AI-driven ultrasound platform expands with new chips, software, and global partnerships.BFLY
44th Annual J.P. Morgan Healthcare Conference26 Feb 2026 - Record Q4 revenue, positive cash flow, and strong U.S. growth set stage for 2026 expansion.BFLY
Q4 202526 Feb 2026 - Revolutionizing ultrasound with digital, AI-enabled devices and strategic licensing for growth.BFLY
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Q3 revenue up 33%, net loss narrowed, and guidance raised amid global and AI expansion.BFLY
Q3 202417 Jan 2026 - Handheld ultrasound innovation, AI, and global expansion drive strong growth and future disruption.BFLY
2024 CG MedTech, Diagnostics and Digital Health & Services Forum13 Jan 2026 - Advanced handheld ultrasound, AI, and services drive rapid growth and market expansion.BFLY
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - iQ3 launch, global expansion, and AI-driven HomeCare initiatives set the stage for strong growth.BFLY
Oppenheimer 35th Annual Health Care MedTech and Services Conference26 Dec 2025 - Butterfly’s handheld ultrasound aims for mass adoption, leveraging AI and chip licensing for growth.BFLY
Evercore ISI 8th Annual HealthCONx Conference3 Dec 2025